Free Trial
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel Free GOVX Stock Alerts

GeoVax Labs (GOVX) Financials

GeoVax Labs logo
$1.71 -0.33 (-16.18%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$1.80 +0.09 (+5.38%)
As of 11/13/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for GeoVax Labs

Annual Income Statements for GeoVax Labs

This table shows GeoVax Labs' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -2.69 -3.27 -2.17 -2.56 -2.37 -2.96 -19 -14 -26 -25 -21
Consolidated Net Income / (Loss)		 -2.69 -3.27 -2.17 -2.56 -2.37 -2.96 -19 -14 -26 -25 -21
Net Income / (Loss) Continuing Operations		 -2.69 -3.27 -2.17 -2.56 -2.37 -2.96 -19 -14 -26 -25 -21
Total Pre-Tax Income 		-2.69 -3.27 -2.17 -2.56 -2.37 -2.96 -19 -14 -26 -25 -21
Total Operating Income		 -2.69 -3.27 -2.17 -2.56 -2.37 -2.82 -19 -14 -27 -25 -22
Total Gross Profit		 0.43 0.83 1.08 0.96 1.18 1.82 0.39 0.08 0.00 3.95 2.49
Total Revenue		 0.43 0.83 1.08 0.96 1.18 1.82 0.39 0.08 0.00 3.95 2.49
Operating Revenue		 0.43 0.83 1.08 0.96 1.18 1.82 0.39 0.08 0.00 3.95 2.49
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 3.12 4.10 3.25 3.53 3.55 4.64 19 14 27 29 24
Selling, General & Admin Expense		 1.43 2.13 1.23 1.65 1.64 2.20 3.58 4.99 6.02 5.39 6.01
Research & Development Expense		 1.69 1.97 2.02 1.88 1.91 2.44 16 9.12 21 24 18
Total Other Income / (Expense), net		 0.01 0.00 0.00 0.00 0.00 -0.14 0.18 0.00 0.78 0.15 0.17
Interest Expense		 - 0.00 0.00 0.00 0.00 0.14 -0.17 - - 0.02 0.00
Interest & Investment Income		 0.01 0.00 0.00 0.01 0.01 0.00 0.00 - 0.78 0.17 0.17
Other Gains / (Losses), net		 - - - - 0.00 - - - - 0.15 0.17
Basic Earnings per Share		 ($0.08) ($0.08) ($0.03) ($15,610.33) ($781.87) ($2.14) ($3.04) ($12.39) ($14.29) ($120.46) ($22.40)
Weighted Average Basic Shares Outstanding		 31.95M 41.52M 68.61M 164.00 3.03K 1.38M 6.10M 1.13M 1.82M 207.48K 958.44K

Quarterly Income Statements for GeoVax Labs

This table shows GeoVax Labs' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -5.85 -5.06 -5.82 -8.26 -5.36 -5.37 -6.32 -4.42 -5.26 -4.43 -4.16
Consolidated Net Income / (Loss)		 -5.85 -5.06 -5.82 -8.26 -5.36 -5.37 -6.32 -4.42 -5.26 -4.43 -4.16
Net Income / (Loss) Continuing Operations		 -5.85 -5.07 -5.78 -8.15 -5.36 -5.37 -6.32 -4.35 -5.26 -4.43 -4.16
Total Pre-Tax Income 		-5.85 -5.06 -5.82 -8.26 -5.36 -5.37 -6.32 -4.42 -5.26 -4.43 -4.16
Total Operating Income		 -5.88 -5.06 -5.85 -8.34 -5.41 -5.42 -6.37 -4.44 -5.27 -4.44 -4.17
Total Gross Profit		 0.00 0.30 2.79 0.86 1.64 0.85 0.00 - 0.00 0.00 0.00
Total Revenue		 0.00 0.30 2.79 0.86 1.64 0.85 0.00 - 0.00 0.00 0.00
Operating Revenue		 0.00 0.30 2.79 0.86 1.64 0.85 0.00 - 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses		 5.88 5.36 8.64 9.21 7.04 6.27 6.37 4.44 5.27 4.44 4.17
Selling, General & Admin Expense		 1.46 1.09 1.24 1.60 1.69 1.54 1.33 1.45 1.37 1.33 1.35
Research & Development Expense		 4.43 4.28 7.40 7.61 5.35 4.73 5.04 2.99 3.90 3.11 2.82
Total Other Income / (Expense), net		 0.03 -0.00 0.04 0.08 0.05 0.05 0.05 0.02 0.01 0.02 0.02
Interest & Investment Income		 0.03 0.01 0.05 0.08 0.05 0.05 0.05 0.02 0.01 0.02 0.02
Basic Earnings per Share		 ($2.47) ($1.99) ($0.91) ($39.82) ($11.20) ($8.74) ($150.68) ($4.61) ($2.62) ($0.97) ($10.56)
Weighted Average Basic Shares Outstanding		 2.37M 2.54M 6.40M 207.48K 478.19K 614.37K 41.94K 958.44K 2.01M 4.57M 393.55K
Weighted Average Diluted Shares Outstanding		 2.31M 5.26M 9.44M 13.84M 15.19M 25.36M 29.71M 0.00 3.47M 7.37M 544.45K
Weighted Average Basic & Diluted Shares Outstanding		 2.31M 5.26M 9.44M 13.84M 15.19M 25.36M 29.71M 0.00 3.47M 7.37M 544.45K

Annual Cash Flow Statements for GeoVax Labs

This table details how cash moves in and out of GeoVax Labs' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -0.04 -0.61 -0.14 -0.05 0.02 9.60 1.54 16 -21 -0.95 -2.42
Net Cash From Operating Activities		 -2.71 -1.95 -1.69 -1.54 -1.40 -2.75 -11 -19 -25 -25 -21
Net Cash From Continuing Operating Activities		 -2.71 -1.95 -1.69 -1.49 -1.40 -2.75 -11 -19 -25 -25 -21
Net Income / (Loss) Continuing Operations		 -2.69 -3.27 -2.17 -2.56 -2.37 -2.96 -19 -14 -26 -25 -21
Consolidated Net Income / (Loss)		 -2.69 -3.27 -2.17 -2.56 -2.37 -2.96 -19 -14 -26 -25 -21
Depreciation Expense		 0.03 0.03 0.03 0.02 0.01 0.02 0.04 0.06 0.07 0.10 0.07
Non-Cash Adjustments To Reconcile Net Income		 0.07 0.97 0.06 0.47 0.33 0.06 0.41 0.90 1.07 0.53 1.12
Changes in Operating Assets and Liabilities, net		 -0.11 0.33 0.40 0.53 0.64 -0.00 6.93 -5.97 -0.36 -0.31 -1.19
Net Cash From Investing Activities		 -0.02 0.00 -0.00 0.00 -0.01 -0.16 -0.05 -0.13 -0.05 -0.02 -0.03
Net Cash From Continuing Investing Activities		 -0.02 0.00 -0.00 0.00 -0.01 -0.16 -0.05 -0.13 -0.05 -0.02 -0.03
Purchase of Property, Plant & Equipment		 -0.02 0.00 -0.00 0.00 -0.01 -0.16 -0.05 -0.13 -0.05 -0.02 -0.03
Net Cash From Financing Activities		 2.68 1.34 1.55 1.49 1.43 13 13 35 4.06 24 19
Net Cash From Continuing Financing Activities		 2.68 1.34 1.55 1.49 1.43 13 13 35 4.06 24 19
Repayment of Debt		 - - - 0.00 -0.01 -0.01 -0.03 - 0.00 -0.15 0.00
Issuance of Debt		 - 0.00 0.00 0.30 0.00 1.06 - - 0.00 0.14 0.00
Issuance of Common Equity		 0.00 1.34 0.57 - 0.00 11 9.41 28 0.00 21 19
Other Financing Activities, net		 - - - - 0.00 0.00 3.40 7.63 4.06 2.37 0.16

Quarterly Cash Flow Statements for GeoVax Labs

This table details how cash moves in and out of GeoVax Labs' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents		 -7.45 2.56 7.03 -3.09 1.93 -4.34 1.92 -1.92 -1.81 1.87 -0.99
Net Cash From Operating Activities		 -5.68 -1.94 -9.30 -7.75 -5.97 -4.33 -6.21 -4.96 -3.54 -3.66 -4.34
Net Cash From Continuing Operating Activities		 -7.45 -0.18 -9.30 -7.75 -5.97 -4.33 -6.21 -4.96 -3.54 -3.66 -4.34
Net Income / (Loss) Continuing Operations		 -5.85 -5.06 -5.82 -8.26 -5.36 -5.37 -6.32 -4.42 -5.26 -4.43 -4.16
Consolidated Net Income / (Loss)		 -5.85 -5.06 -5.82 -8.26 -5.36 -5.37 -6.32 -4.42 -5.26 -4.43 -4.16
Depreciation Expense		 0.02 0.02 0.03 0.02 0.02 0.02 0.02 0.02 0.01 0.01 0.01
Non-Cash Adjustments To Reconcile Net Income		 0.16 0.10 0.13 0.14 0.29 0.29 0.28 0.25 0.22 0.16 0.28
Changes in Operating Assets and Liabilities, net		 -1.78 4.76 -3.64 0.35 -0.92 0.73 -0.19 -0.81 1.49 0.59 -0.47
Net Cash From Investing Activities		 0.00 - -0.02 - -0.02 -0.01 - - 0.00 - 0.01
Net Cash From Continuing Investing Activities		 0.00 - -0.02 - -0.02 -0.01 - - 0.00 - 0.01
Net Cash From Financing Activities		 0.00 2.73 16 4.67 7.91 0.00 8.13 3.04 1.72 5.53 3.34
Net Cash From Continuing Financing Activities		 0.00 2.73 16 4.67 7.91 0.00 8.13 3.04 1.72 5.53 3.34
Issuance of Common Equity		 0.00 1.21 16 4.67 7.91 - 7.97 3.04 1.72 3.55 3.34

Annual Balance Sheets for GeoVax Labs

This table presents GeoVax Labs' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 1.33 0.61 0.49 0.64 0.47 10 12 31 9.28 8.16 6.34
Total Current Assets		 1.24 0.54 0.45 0.62 0.45 10 12 29 7.89 7.93 5.31
Cash & Equivalents		 1.06 0.45 0.31 0.26 0.28 9.88 11 28 6.45 5.51 3.09
Prepaid Expenses		 0.06 0.06 0.08 0.24 0.10 0.17 0.16 1.33 1.43 1.77 2.23
Plant, Property, & Equipment, net		 0.08 0.05 0.03 0.01 0.01 0.15 0.16 0.23 0.21 0.15 0.11
Total Noncurrent Assets		 0.01 0.01 0.01 0.01 0.01 0.01 0.01 2.17 1.19 0.07 0.92
Other Noncurrent Operating Assets		 0.01 0.01 0.01 0.01 0.01 0.01 - - - - 0.92
Total Liabilities & Shareholders' Equity		 1.33 0.61 0.49 0.64 0.47 10 12 31 9.28 8.16 6.34
Total Liabilities		 0.13 0.37 0.81 1.66 2.04 0.83 7.44 4.75 3.52 3.11 2.52
Total Current Liabilities		 0.13 0.37 0.81 1.62 2.02 0.81 5.44 4.75 3.52 3.11 1.94
Accounts Payable		 0.10 0.08 0.08 0.13 0.15 0.27 2.06 1.75 2.80 1.85 0.79
Accrued Expenses		 0.03 0.29 0.73 1.24 1.85 0.36 3.38 3.00 0.72 1.26 0.88
Other Current Liabilities		 - - - - - - - - - - 0.26
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.04 0.03 0.01 2.00 0.00 0.00 0.00 0.58
Other Noncurrent Operating Liabilities		 - - - - - - 2.00 - - - 0.58
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 - - - 0.00 0.00
Total Equity & Noncontrolling Interests		 1.20 0.24 -0.32 -2.99 -1.57 9.57 4.36 27 5.76 5.05 3.83
Total Preferred & Common Equity		 2.26 1.26 -0.32 -1.02 -1.57 9.57 4.36 27 5.76 5.05 3.83
Total Common Equity		 0.14 -0.78 -2.22 -2.99 -3.51 9.49 4.36 27 5.76 5.05 3.83
Common Stock		 33 35 36 37 39 55 69 105 110 134 155
Retained Earnings		 -32 -36 -38 -40 -43 -46 -64 -78 -104 -129 -151

Quarterly Balance Sheets for GeoVax Labs

This table presents GeoVax Labs' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets		 3.36 4.10 11 11 5.35 6.73 2.98 4.64 3.42
Total Current Assets		 2.86 3.84 11 11 5.14 6.52 2.43 4.18 3.11
Cash & Equivalents		 0.77 1.56 8.59 7.44 3.09 5.01 1.27 3.14 2.15
Prepaid Expenses		 2.09 1.98 1.73 1.68 1.51 1.51 1.16 1.03 0.96
Plant, Property, & Equipment, net		 0.19 0.17 0.17 0.15 0.14 0.13 0.10 0.08 0.01
Total Noncurrent Assets		 0.31 0.08 0.07 0.07 0.07 0.09 0.45 0.38 0.30
Other Noncurrent Operating Assets		 - - - - - - 0.45 0.38 0.30
Total Liabilities & Shareholders' Equity		 3.36 4.10 11 11 5.35 6.73 2.98 4.64 3.42
Total Liabilities		 3.30 6.40 2.61 2.94 2.53 1.82 2.49 2.88 2.28
Total Current Liabilities		 3.30 6.40 2.61 2.94 2.53 1.82 2.29 2.71 2.14
Accounts Payable		 1.88 3.98 2.15 2.40 1.83 0.98 1.43 1.83 1.26
Accrued Expenses		 1.42 2.28 0.46 0.53 0.70 0.85 0.66 0.72 0.77
Other Current Liabilities		 - - - - - - 0.20 0.15 0.11
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 0.00 0.00 0.20 0.17 0.14
Other Noncurrent Operating Liabilities		 - - - - - - 0.20 0.17 0.14
Commitments & Contingencies		 - - - - - - - - 0.00
Total Equity & Noncontrolling Interests		 0.05 -2.31 8.50 7.90 2.82 4.91 0.49 1.76 1.15
Total Preferred & Common Equity		 0.05 -2.31 8.50 7.90 2.82 4.91 0.49 1.76 1.15
Total Common Equity		 0.05 -2.31 8.50 7.90 2.82 4.91 0.49 1.76 1.15
Common Stock		 110 113 130 143 143 151 157 162 166
Retained Earnings		 -110 -115 -121 -135 -140 -146 -156 -161 -165

Annual Metrics And Ratios for GeoVax Labs

This table displays calculated financial ratios and metrics derived from GeoVax Labs' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 31,950,813.00 49,172,733.00 83,913,900.00 196,903,476.00 426,306,328.00 3,810,836.00 6,381,541.00 26,334,953.00 26,695,287.00 9,436,069.00 29,705,360.00
DEI Adjusted Shares Outstanding		 85,202.00 131,127.00 223,770.00 525,076.00 1,136,817.00 10,162.00 17,017.00 70,227.00 71,187.00 377,443.00 1,188,214.00
DEI Earnings Per Adjusted Shares Outstanding		 -31.56 -24.95 -9.70 -4.88 -2.09 -291.09 -1,091.28 -199.65 -364.77 -66.21 -18.06
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -51.52% 93.64% 29.72% -10.42% 22.08% 55.09% -78.86% -78.85% -100.00% 0.00% -37.06%
EBITDA Growth		 0.10% -21.71% 33.85% -18.47% 7.03% -13.06% -599.87% 25.31% -90.87% 6.07% 13.89%
EBIT Growth		 1.57% -21.47% 33.57% -17.86% 7.42% -18.73% -565.50% 25.16% -90.63% 5.98% 13.94%
NOPAT Growth		 1.57% -21.47% 33.57% -17.86% 7.42% -18.73% -565.50% 25.16% -90.63% 5.98% 13.94%
Net Income Growth		 1.62% -21.66% 33.67% -17.97% 7.40% -24.78% -527.79% 24.50% -85.20% 3.75% 14.11%
EPS Growth		 20.00% 0.00% 62.50% -52,034,333.33% 94.99% 99.73% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Growth		 -20.23% 28.06% 13.24% 8.61% 9.37% -96.68% -307.06% -69.97% -32.28% 1.98% 12.97%
Free Cash Flow Firm Growth		 -1.98% 2.65% 43.00% -31.18% 42.96% -345.41% -67.87% -122.29% -46.14% 5.40% 13.37%
Invested Capital Growth		 223.99% -248.11% -196.63% -54.95% -85.14% 93.57% -5,951.66% 54.94% 41.10% 71.80% 239.66%
Revenue Q/Q Growth		 -12.84% 1.83% 0.42% 14.22% -2.55% -0.92% -18.35% -66.93% 0.00% 27.97% -25.78%
EBITDA Q/Q Growth		 7.59% -8.06% 16.32% -4.93% 1.70% -37.71% -197.14% 37.43% -9.43% -2.67% 15.31%
EBIT Q/Q Growth		 7.89% -7.99% 16.14% -4.79% 1.79% -36.03% -195.71% 37.33% -9.44% -2.66% 15.28%
NOPAT Q/Q Growth		 7.89% -7.99% 16.14% -4.79% 1.79% -36.03% -195.71% 37.33% -9.44% -2.66% 15.28%
Net Income Q/Q Growth		 7.91% -8.01% 16.19% -4.84% 1.81% -33.72% -201.28% 37.35% -9.30% -2.76% 15.19%
EPS Q/Q Growth		 11.11% 11.11% 25.00% -238,590.06% 96.40% -100.04% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 -4.92% 16.77% -4.97% -3.56% 13.63% -84.68% -84.91% -2.04% -14.63% 9.28% 11.51%
Free Cash Flow Firm Q/Q Growth		 4.79% 2.08% 16.76% -30.69% 37.91% -51.02% -25.83% -6.44% -31.38% 12.85% 8.03%
Invested Capital Q/Q Growth		 144.89% -141.44% -9.32% 17.16% -17.42% 79.34% -6,755.91% -10.05% 60.53% -231.60% 491.49%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 100.00% 100.00%
EBITDA Margin		 -622.74% -391.42% -199.62% -264.01% -201.05% -146.57% -4,852.72% -17,138.43% 0.00% -633.42% -866.57%
Operating Margin		 -629.50% -394.90% -202.22% -266.06% -201.76% -154.46% -4,862.72% -17,207.47% 0.00% -635.83% -869.34%
EBIT Margin		 -629.50% -394.90% -202.22% -266.06% -201.76% -154.46% -4,862.72% -17,207.47% 0.00% -635.83% -869.34%
Profit (Net Income) Margin		 -628.22% -394.70% -201.82% -265.79% -201.60% -162.21% -4,817.19% -17,198.35% 0.00% -631.98% -862.34%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 99.95% 100.00% 100.00% 100.00%
Interest Burden Percent		 99.80% 99.95% 99.80% 99.90% 99.92% 105.01% 99.06% 100.00% 97.10% 99.40% 99.19%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -1,998.45% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -14,427.75%
ROIC Less NNEP Spread (ROIC-NNEP)		 -1,924.17% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -14,281.91%
Return on Net Nonoperating Assets (RNNOA)		 1,769.65% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 13,943.96%
Return on Equity (ROE)		 -228.80% -452.84% 5,379.21% 154.47% 103.79% -74.00% -266.61% -90.57% -160.47% -462.31% -483.79%
Cash Return on Invested Capital (CROIC)		 -2,104.11% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,220.22%
Operating Return on Assets (OROA)		 -202.25% -337.15% -395.19% -452.66% -427.11% -51.86% -168.95% -65.03% 0.00% -288.37% -298.52%
Return on Assets (ROA)		 -201.84% -336.97% -394.41% -452.19% -426.78% -54.46% -167.37% -65.00% 0.00% -286.62% -296.11%
Return on Common Equity (ROCE)		 -125.63% 198.02% 199,774.35% 242.97% 147.69% -55.41% -265.16% -90.57% -160.47% -462.31% -483.79%
Return on Equity Simple (ROE_SIMPLE)		 -118.75% -260.24% 675.94% 250.41% 150.56% -30.91% -425.76% -52.71% -450.55% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.89 -2.29 -1.52 -1.79 -1.66 -1.97 -13 -9.82 -19 -18 -15
NOPAT Margin		 -440.65% -276.43% -141.56% -186.24% -141.23% -108.12% -3,403.90% -12,045.23% 0.00% -445.08% -608.54%
Net Nonoperating Expense Percent (NNEP)		 -74.28% -129.47% -169.04% 90.20% 80.30% -19.87% -51.59% -20.38% -38.72% -111.83% -145.84%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -324.81% -348.64% -396.00%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 333.99% 257.13% 114.61% 171.02% 139.27% 120.42% 927.92% 6,116.59% 0.00% 136.18% 241.31%
R&D to Revenue		 395.51% 237.76% 187.61% 195.04% 162.49% 134.04% 4,034.79% 11,190.88% 0.00% 599.65% 728.02%
Operating Expenses to Revenue		 729.50% 494.90% 302.22% 366.06% 301.76% 254.46% 4,962.72% 17,307.47% 0.00% 735.83% 969.34%
Earnings before Interest and Taxes (EBIT)		 -2.69 -3.27 -2.17 -2.56 -2.37 -2.82 -19 -14 -27 -25 -22
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -2.67 -3.24 -2.15 -2.54 -2.36 -2.67 -19 -14 -27 -25 -22
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 44.20 0.00 0.00 0.00 0.00 1.36 5.30 0.62 1.67 4.62 1.33
Price to Tangible Book Value (P/TBV)		 44.20 0.00 0.00 0.00 0.00 1.36 5.30 0.62 1.67 4.62 1.33
Price to Revenue (P/Rev)		 14.93 11.86 15.61 4.09 0.11 7.06 59.93 203.57 0.00 5.89 2.04
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 44.30 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.70
Enterprise Value to Revenue (EV/Rev)		 14.93 12.54 17.08 4.13 1.55 1.79 30.29 0.00 0.00 4.50 0.80
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 -0.10 -0.03 0.02 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 -0.01 -0.02 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.92 -1.05 9.50 -0.51 -0.39 -1.24 -1.52 -1.33 -1.16 -1.22 -0.98
Leverage Ratio		 1.13 1.34 -13.64 -0.34 -0.24 1.36 1.59 1.39 1.26 1.61 1.63
Compound Leverage Factor		 1.13 1.34 -13.61 -0.34 -0.24 1.43 1.58 1.39 1.22 1.60 1.62
Debt to Total Capital		 0.00% 0.00% 0.00% -11.14% -2.59% 2.03% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% -9.67% -0.81% 1.88% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% -1.47% -1.78% 0.15% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 88.00% 423.01% -591.51% 0.00% -125.91% 0.78% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 12.00% -323.01% 691.51% 111.14% 228.50% 97.19% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 -0.12 -0.02 -0.07 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 -0.02 0.10 3.62 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 -0.02 -0.01 -0.01 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 -0.17 -0.02 -0.10 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 -0.02 0.15 4.91 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 -0.02 -0.02 -0.01 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -9.31 -82.06 -109.20 -100.39 -146.10 3.57 -10.36 -1.95 -23.04 -26.68 -42.31
Noncontrolling Interest Sharing Ratio		 45.09% 143.73% -3,613.82% -57.29% -42.30% 25.12% 0.55% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 9.74 1.47 0.55 0.38 0.22 12.63 2.14 6.10 2.24 2.55 2.74
Quick Ratio		 8.35 1.23 0.39 0.16 0.14 12.20 2.10 5.82 1.83 1.98 1.59
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -1.99 -1.93 -1.10 -1.45 -0.82 -3.67 -6.17 -14 -20 -19 -16
Operating Cash Flow to CapEx		 -17,067.91% 0.00% -38,815.26% 0.00% -18,386.76% -1,754.29% -23,463.72% -14,174.36% -51,431.45% -119,476.64% -77,770.42%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 -558.16 -183.46 -25.59 0.00 0.00 0.00 -886.49 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 -595.76 -311.12 -19.16 0.00 0.00 0.00 -1,154.41 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 -595.76 -312.81 -20.26 0.00 0.00 0.00 -1,155.38 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.32 0.85 1.95 1.70 2.12 0.34 0.03 0.00 0.00 0.45 0.34
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 4.75 11.98 25.01 45.33 107.11 23.03 2.53 0.42 0.00 21.99 19.24
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.14 -0.21 -0.63 -0.98 -1.82 -0.12 -7.07 -3.19 -1.88 -0.53 0.74
Invested Capital Turnover		 4.54 -23.89 -2.54 -1.19 -0.84 -1.88 -0.11 -0.02 0.00 -3.29 23.71
Increase / (Decrease) in Invested Capital		 0.10 -0.36 -0.42 -0.35 -0.84 1.70 -6.96 3.89 1.31 1.35 1.27
Enterprise Value (EV)		 6.39 10 18 3.98 1.82 3.27 12 -11 3.18 18 1.99
Market Capitalization		 6.39 9.83 17 3.94 0.13 13 23 17 9.64 23 5.08
Book Value per Share		 $0.00 ($0.02) ($0.03) ($0.02) ($0.01) $2.49 $0.68 $1.01 $0.22 $0.54 $0.13
Tangible Book Value per Share		 $0.00 ($0.02) ($0.03) ($0.02) ($0.01) $2.49 $0.68 $1.01 $0.22 $0.54 $0.13
Total Capital		 1.20 0.24 -0.32 -2.69 -1.53 9.77 4.36 27 5.76 5.05 3.83
Total Debt		 0.00 0.00 0.00 0.30 0.04 0.20 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.04 0.03 0.01 0.00 0.00 0.00 0.00 0.00
Net Debt		 -1.06 -0.45 -0.31 0.04 -0.24 -9.69 -11 -28 -6.45 -5.51 -3.09
Capital Expenditures (CapEx)		 0.02 0.00 0.00 0.00 0.01 0.16 0.05 0.13 0.05 0.02 0.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.05 -0.28 -0.68 -1.00 -1.84 -0.28 -5.23 -3.42 -2.09 -0.68 0.29
Debt-free Net Working Capital (DFNWC)		 1.11 0.17 -0.36 -0.74 -1.56 9.61 6.19 24 4.37 4.83 3.38
Net Working Capital (NWC)		 1.11 0.17 -0.36 -1.01 -1.57 9.42 6.19 24 4.37 4.83 3.38
Net Nonoperating Expense (NNE)		 0.80 0.98 0.65 0.77 0.71 0.99 5.45 4.20 7.25 7.39 6.32
Net Nonoperating Obligations (NNO)		 -1.06 -0.45 -0.31 2.01 -0.24 -9.69 -11 -30 -7.64 -5.58 -3.09
Total Depreciation and Amortization (D&A)		 0.03 0.03 0.03 0.02 0.01 0.14 0.04 0.06 0.07 0.10 0.07
Debt-free, Cash-free Net Working Capital to Revenue		 11.60% -33.72% -62.86% -104.28% -156.46% -15.11% -1,356.71% -4,197.31% 0.00% -17.18% 11.74%
Debt-free Net Working Capital to Revenue		 259.29% 21.06% -33.78% -77.32% -132.36% 526.86% 1,606.68% 29,672.54% 0.00% 122.08% 135.71%
Net Working Capital to Revenue		 259.29% 21.06% -33.78% -104.35% -133.42% 516.81% 1,606.68% 29,672.54% 0.00% 122.08% 135.71%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.20) ($1.20) ($0.45) ($0.30) ($588.75) ($32.10) ($45.60) ($12.45) ($14.29) ($120.50) ($22.40)
Adjusted Weighted Average Basic Shares Outstanding		 2.47M 3.75M 8.78M 18.54M 919.44K 421.03K 472.60K 1.13M 1.82M 207.48K 958.44K
Adjusted Diluted Earnings per Share		 ($1.20) ($1.20) ($0.45) ($0.30) ($588.75) ($32.10) ($45.60) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 2.47M 3.75M 8.78M 18.54M 919.44K 421.03K 472.60K 1.76M 2.17M 553.58K 0.00
Adjusted Basic & Diluted Earnings per Share		 ($1.20) ($1.20) ($0.45) ($0.30) ($588.75) ($32.10) ($45.60) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 2.13M 2.77M 4.57M 10.91M 4.03K 92.26K 406.66K 1.76M 2.17M 553.58K 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -1.89 -2.29 -1.52 -1.79 -1.66 -1.97 -13 -9.82 -19 -18 -15
Normalized NOPAT Margin		 -440.65% -276.43% -141.56% -186.24% -141.23% -108.12% -3,403.90% -12,045.23% 0.00% -445.08% -608.54%
Pre Tax Income Margin		 -628.22% -394.70% -201.82% -265.79% -201.60% -162.21% -4,817.19% -17,207.47% 0.00% -631.98% -862.34%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 -989.47 -527.81 -19.63 0.00 0.00 0.00 -1,176.34 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 -692.63 -369.47 -13.74 0.00 0.00 0.00 -823.44 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 -989.47 -529.50 -20.72 0.00 0.00 0.00 -1,177.31 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 -692.63 -371.16 -14.83 0.00 0.00 0.00 -824.40 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for GeoVax Labs

This table displays calculated financial ratios and metrics derived from GeoVax Labs' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding		 2,172,272.00 2,308,309.00 5,263,700.00 9,436,069.00 13,839,478.00 15,193,593.00 25,359,593.00 29,705,360.00 29,705,360.00 3,473,260.00 7,369,243.00
DEI Adjusted Shares Outstanding		 86,891.00 92,332.00 210,548.00 377,443.00 553,579.00 607,744.00 1,014,384.00 1,188,214.00 1,188,214.00 3,473,260.00 307,052.00
DEI Earnings Per Adjusted Shares Outstanding		 -67.33 -54.85 -27.62 -21.89 -9.68 -8.84 -6.23 -3.72 -4.43 -1.27 -13.54
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 183.45% -100.00% 0.00% -100.00% -100.00% 0.00%
EBITDA Growth		 -37.86% 18.23% 32.14% -8.49% 8.11% -7.22% -9.14% 46.85% 2.37% 18.00% 34.46%
EBIT Growth		 -37.76% 18.07% 31.92% -8.46% 8.12% -7.05% -8.86% 46.77% 2.45% 18.03% 34.50%
NOPAT Growth		 -37.76% 18.07% 31.92% -8.46% 8.12% -7.05% -8.86% 46.77% 2.45% 18.03% 34.50%
Net Income Growth		 -44.88% 14.57% 30.84% -8.83% 8.42% -6.04% -8.66% 46.53% 1.79% 17.57% 34.23%
EPS Growth		 0.00% 0.00% 0.00% -8.83% 0.00% 0.00% 0.00% 46.53% 0.00% 0.00% 0.00%
Operating Cash Flow Growth		 -51.05% 67.85% -82.45% 24.56% -4.96% -123.30% 33.18% 36.01% 40.70% 15.60% 30.13%
Free Cash Flow Firm Growth		 7.54% 71.85% -108.98% -7.37% 1.67% -366.22% 49.02% 39.10% 51.37% 71.48% 52.45%
Invested Capital Growth		 53.25% -108.96% 96.64% 71.80% 138.05% 90.98% -18.29% 239.66% -300.38% -302.33% -431.27%
Revenue Q/Q Growth		 0.00% 0.00% 827.73% -69.01% 89.36% -47.93% -100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 23.57% 14.07% -15.59% -42.90% 35.26% -0.26% -17.67% 30.41% -18.93% 15.79% 5.96%
EBIT Q/Q Growth		 23.53% 13.95% -15.65% -42.53% 35.22% -0.25% -17.61% 30.31% -18.71% 15.76% 6.02%
NOPAT Q/Q Growth		 23.53% 13.95% -15.65% -42.53% 35.22% -0.25% -17.61% 30.31% -18.71% 15.76% 6.02%
Net Income Q/Q Growth		 22.95% 13.44% -14.84% -42.08% 35.16% -0.23% -17.68% 30.08% -19.09% 15.88% 6.11%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 44.70% 65.85% -378.98% 16.60% 23.06% 27.34% -43.32% 20.13% 28.70% -3.40% -18.66%
Free Cash Flow Firm Q/Q Growth		 21.14% 70.51% -458.37% 17.31% 27.77% -39.81% 38.95% 1.22% 42.33% 18.00% -1.80%
Invested Capital Q/Q Growth		 45.64% -273.40% 95.81% -231.60% 173.34% -188.52% 45.05% 491.49% -205.22% -77.73% 27.43%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% -1,675.71% -208.79% -962.82% -329.18% -633.84% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% -1,683.61% -209.88% -965.32% -330.22% -635.81% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% -1,683.61% -209.88% -965.32% -330.22% -635.81% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% -1,684.21% -208.48% -955.87% -327.31% -630.05% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 99.44% 100.04% 99.33% 99.02% 99.12% 99.09% 99.15% 99.47% 99.79% 99.65% 99.56%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -242.41% -362.39% -276.02% -462.31% -616.17% -9,690.24% -377.44% 0.00% -509.28% -891.59% -603.27%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% -4,810.03% 0.00% 0.00% -2,220.22% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% -39.95% -47.49% -437.80% -260.21% -827.02% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% -39.96% -47.17% -433.51% -257.92% -819.53% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -242.41% -362.39% -276.02% -462.31% -616.17% -9,690.24% -377.44% 0.00% -509.28% -891.59% -603.27%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -4.12 -3.54 -4.10 -5.84 -3.78 -3.79 -4.46 -3.11 -3.69 -3.11 -2.92
NOPAT Margin		 0.00% -1,178.53% -146.92% -675.73% -231.15% -445.07% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -13.26% -14.84% -15.24% -36.64% -36.67% -67.59% -27.00% -30.22% -35.78% -41.76% -34.05%
Return On Investment Capital (ROIC_SIMPLE)		 -7,587.58% 163.53% -48.19% -115.70% -47.91% -134.45% -90.91% -81.28% -747.52% -176.60% -254.64%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 361.19% 44.49% 185.18% 103.09% 180.95% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 1,422.41% 265.39% 880.15% 327.13% 554.86% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 1,783.61% 309.88% 1,065.32% 430.22% 735.81% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -5.88 -5.06 -5.85 -8.34 -5.41 -5.42 -6.37 -4.44 -5.27 -4.44 -4.17
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -5.86 -5.04 -5.82 -8.32 -5.39 -5.40 -6.36 -4.42 -5.26 -4.43 -4.17
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 80.05 0.00 1.49 4.62 1.86 4.66 2.45 1.33 3.32 2.51 2.15
Price to Tangible Book Value (P/TBV)		 80.05 0.00 1.49 4.62 1.86 4.66 2.45 1.33 3.32 2.51 2.15
Price to Revenue (P/Rev)		 0.00 24.45 4.11 5.89 2.62 2.14 3.58 2.04 1.92 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 18.62 0.00 0.00 2.70 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 19.73 1.32 4.50 1.29 1.64 2.08 0.80 0.43 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 -0.06 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.14 -1.38 -1.28 -1.22 -1.08 -9.11 -1.03 -0.98 -1.05 -1.38 -1.20
Leverage Ratio		 1.34 1.71 1.55 1.61 1.78 18.45 1.33 1.63 1.65 2.18 1.68
Compound Leverage Factor		 1.33 1.71 1.54 1.60 1.77 18.28 1.32 1.63 1.64 2.17 1.67
Debt to Total Capital		 0.00% -6.57% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% -6.57% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 106.57% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 -0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.05 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 -0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.07 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -51.10 -43.48 -12.91 -19.89 -14.69 -35.14 -28.29 -33.36 -78.36 -50.26 -70.35
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.87 0.60 4.17 2.55 3.62 2.03 3.57 2.74 1.06 1.54 1.46
Quick Ratio		 0.23 0.29 3.50 1.98 3.04 1.43 2.75 1.59 0.56 1.16 1.01
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -5.28 -1.56 -8.69 -7.19 -5.19 -7.26 -4.43 -4.38 -2.52 -2.07 -2.11
Operating Cash Flow to CapEx		 0.00% 0.00% -45,016.14% 0.00% -35,312.42% -40,440.36% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 -213.53 -617.34 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 -266.19 -660.17 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 -266.19 -661.64 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.02 0.23 0.45 0.79 1.30 0.38 0.34 0.12 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 14.74 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 1.52 16.07 21.99 32.89 39.08 22.46 19.24 6.91 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 24.76 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 24.76 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -1.02 -3.81 -0.16 -0.53 0.39 -0.34 -0.19 0.74 -0.78 -1.38 -1.00
Invested Capital Turnover		 0.00 -0.11 -1.26 -3.29 -17.69 -2.96 -19.24 23.71 -4.37 0.00 0.00
Increase / (Decrease) in Invested Capital		 1.16 -1.99 4.60 1.35 1.41 3.47 -0.03 1.27 -1.17 -1.04 -0.81
Enterprise Value (EV)		 3.58 5.93 4.09 18 7.23 10 6.99 1.99 0.37 1.27 0.31
Market Capitalization		 4.34 7.35 13 23 15 13 12 5.08 1.64 4.41 2.46
Book Value per Share		 $0.02 ($1.00) $1.62 $0.54 $0.57 $0.19 $0.19 $0.13 $0.02 $0.51 $0.16
Tangible Book Value per Share		 $0.02 ($1.00) $1.62 $0.54 $0.57 $0.19 $0.19 $0.13 $0.02 $0.51 $0.16
Total Capital		 0.05 -2.17 8.50 5.05 7.90 2.82 4.91 3.83 0.49 1.76 1.15
Total Debt		 0.00 0.14 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -0.77 -1.42 -8.59 -5.51 -7.44 -3.09 -5.01 -3.09 -1.27 -3.14 -2.15
Capital Expenditures (CapEx)		 0.00 0.00 0.02 0.00 0.02 0.01 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.21 -3.98 -0.33 -0.68 0.24 -0.49 -0.32 0.29 -1.13 -1.68 -1.17
Debt-free Net Working Capital (DFNWC)		 -0.44 -2.42 8.26 4.83 7.68 2.61 4.69 3.38 0.14 1.46 0.98
Net Working Capital (NWC)		 -0.44 -2.56 8.26 4.83 7.68 2.61 4.69 3.38 0.14 1.46 0.98
Net Nonoperating Expense (NNE)		 1.73 1.52 1.72 2.42 1.57 1.58 1.86 1.31 1.57 1.32 1.23
Net Nonoperating Obligations (NNO)		 -1.07 -1.50 -8.66 -5.58 -7.51 -3.16 -5.10 -3.09 -1.27 -3.14 -2.15
Total Depreciation and Amortization (D&A)		 0.02 0.02 0.03 0.02 0.02 0.02 0.02 0.02 0.01 0.01 0.01
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -1,323.74% -10.72% -17.18% 4.26% -7.94% -9.42% 11.74% -132.82% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% -804.35% 267.34% 122.08% 137.30% 42.43% 139.94% 135.71% 16.40% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% -851.67% 267.34% 122.08% 137.30% 42.43% 139.94% 135.71% 16.40% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($2.47) ($1.99) ($0.91) ($995.50) ($11.25) ($8.75) ($0.31) ($115.25) ($2.62) ($0.97) ($10.56)
Adjusted Weighted Average Basic Shares Outstanding		 2.37M 2.54M 6.40M 8.30K 478.19K 614.37K 20.29M 38.34K 2.01M 4.57M 393.55K
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($995.50) $0.00 $0.00 $0.00 ($115.25) $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 2.31M 5.26M 9.44M 553.58K 607.74K 1.01M 29.71M 0.00 3.47M 7.37M 544.45K
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($995.50) $0.00 $0.00 $0.00 ($115.25) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 2.31M 5.26M 9.44M 553.58K 607.74K 1.01M 29.71M 0.00 3.47M 7.37M 544.45K
Normalized Net Operating Profit after Tax (NOPAT)		 -4.12 -3.54 -4.10 -5.84 -3.78 -3.79 -4.46 -3.11 -3.69 -3.11 -2.92
Normalized NOPAT Margin		 0.00% -1,178.53% -146.92% -675.73% -231.15% -445.07% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% -1,684.21% -208.48% -955.87% -327.31% -630.05% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 -694.22 -415.72 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 -485.95 -291.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 -694.22 -417.19 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 -485.95 -292.47 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

GeoVax Labs’ recent statements show some improvement in quarterly losses and operating expenses, but the company remains pre-revenue in the latest periods and continues to use cash to fund operations. Its cash position increased in Q2 2026 largely because of financing inflows, making continued access to funding an important factor for investors to monitor.

  • The net loss narrowed to $4.4 million in Q2 2026 from $5.3 million in Q1 2026 and $6.3 million in Q3 2025.
  • Operating expenses fell to $4.4 million in Q2 2026 from $5.3 million in Q1. Research and development expense, the largest cost, also declined to $3.1 million from $3.9 million.
  • Cash and equivalents rose to $3.1 million at June 30, 2026, up from $1.3 million at the end of Q1. Total current assets exceeded current liabilities by about $1.5 million, and reported shareholders’ equity was positive at $1.8 million.
  • Revenue has been uneven: GeoVax reported revenue in several 2024 and early-2025 quarters, but no revenue in the statements for Q3 2025 through Q2 2026. The supplied data does not explain the source or recurrence of the earlier revenue.
  • The company continues to report substantial losses. Q2 2026 net loss was $4.4 million, and the latest statements show no revenue to offset operating costs.
  • Operating cash flow remained negative at $3.7 million in Q2 2026, compared with negative $3.5 million in Q1. The company has recorded operating cash outflows across the quarters shown, including larger outflows in some 2024 and 2025 periods.
  • Q2’s cash increase depended on financing: GeoVax received $5.5 million from financing activities, including $3.6 million from common equity issuance. This reliance on external funding may expose the company to financing conditions and potential shareholder dilution.
  • Cash remains limited relative to the recent operating cash outflow: the $3.1 million quarter-end balance was below Q2 operating cash use of $3.7 million. The balance-sheet total also includes prepaid expenses, which are not cash available to fund spending.
  • The longer-term cash trend is uneven. Cash was $8.6 million in Q3 2024 and $7.4 million in Q1 2025, before falling to $1.3 million in Q1 2026; the Q2 recovery followed significant financing inflows.
11/15/26 04:32 AM ETAI Generated. May Contain Errors.

GeoVax Labs Financials - Frequently Asked Questions

According to the most recent income statement we have on file, GeoVax Labs' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

GeoVax Labs' net income appears to be on a downward trend, with a most recent value of -$21.46 million in 2025, falling from -$2.69 million in 2015. The previous period was -$24.99 million in 2024. See where experts think GeoVax Labs is headed by visiting GeoVax Labs' forecast page.

GeoVax Labs' total operating income in 2025 was -$21.64 million, based on the following breakdown:
  • Total Gross Profit: $2.49 million
  • Total Operating Expenses: $24.13 million

Over the last 10 years, GeoVax Labs' total revenue changed from $428.08 thousand in 2015 to $2.49 million in 2025, a change of 481.5%.

In the past 10 quarters, GeoVax Labs' cash and equivalents has ranged from $768.86 thousand in Q1 2024 to $8.59 million in Q3 2024, and is currently $2.15 million as of their latest financial filing in Q3 2026.

GeoVax Labs had total debt of $0.00 at the end of 2025, compared with none in 2024, and none in 2015.

Over the last 10 years, GeoVax Labs' book value per share changed from 0.00 in 2015 to 0.13 in 2025, a change of 2,762.2%.


Related Companies

Financial statements for NASDAQ:GOVX last updated on 11/12/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...
Base Camp Trading | Sponsoredtc pixel
Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...
Behind the Markets | Sponsoredtc pixel
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...
Weiss Ratings | Sponsoredtc pixel
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
SHOCKING! Prediction caught on camera
Newly released footage shows James Altucher pulling a document out of a briefcase on camera. It is a document ...
Paradigm Press | Sponsoredtc pixel
Trump’s EO to send this $5 stock ripping higher…?
President Trump's December executive order declared space a national security and economic priority, fueling a...
Traders Agency | Sponsoredtc pixel
Uranium Mine Flood That Sparked a 2006 Price Surge Returns
In 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...
Digest Publishing | Sponsoredtc pixel